Gainers
- Connect Biopharma Hldgs CNTB shares rose 47.3% to $1.62 during Friday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 2307.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $89.1 million.
- Gelesis Holdings GLS shares increased by 32.72% to $0.15. The market value of their outstanding shares is at $10.7 million.
- Biocept BIOC stock increased by 27.22% to $0.3. The company's market cap stands at $5.1 million.
- Clearside Biomedical CLSD stock moved upwards by 21.14% to $1.26. The company's market cap stands at $77.3 million.
- Regulus Therapeutics RGLS shares increased by 18.39% to $1.03. The company's market cap stands at $17.3 million.
- Kineta KA stock moved upwards by 16.82% to $3.75. The company's market cap stands at $31.1 million.
Losers
- ATI Physical Therapy ATIP shares fell 19.8% to $0.33 during Friday's after-market session. The company's market cap stands at $67.4 million. The company's, Q4 earnings came out yesterday.
- Science 37 Hldgs SNCE stock declined by 18.77% to $0.29. Trading volume for this security closed at 334.3K, accounting for 41.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $33.8 million.
- Pieris Pharmaceuticals PIRS shares decreased by 13.23% to $1.05. The market value of their outstanding shares is at $78.1 million.
- Ainos AIMD stock fell 9.61% to $1.36. The market value of their outstanding shares is at $27.1 million.
- Bright Green BGXX shares decreased by 9.59% to $0.86. The company's market cap stands at $145.8 million.
- Sangamo Therapeutics SGMO shares decreased by 8.96% to $1.83. Sangamo Therapeutics's trading volume hit 93.1K shares by close, accounting for 6.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $308.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in